{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:31:45Z","timestamp":1762918305771,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.amjcard.2021.09.047","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T13:17:37Z","timestamp":1639747057000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs"],"prefix":"10.1016","volume":"163","author":[{"given":"Steve","family":"Deitelzweig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janvi","family":"Sah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Russ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Preib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol D.","family":"Dhamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ratiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamuno","family":"Alfred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edi","family":"Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0079-7331","authenticated-orcid":false,"given":"Manuela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2021.09.047_bib0001","unstructured":"Centers for Disease Control and Prevention. Heart disease: Atrial fibrillation. (Available at:) https:\/\/www.cdc.gov\/heartdisease\/atrial_fibrillation.htm. Date: September 8, 2020. Accessed January 8, 2021."},{"issue":"1","key":"10.1016\/j.amjcard.2021.09.047_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.amjcard.2021.09.047_bib0003","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2021.09.047_bib0004","series-title":"Stroke Prevention in Patients with Atrial Fibrillation: A Systematic Review Update","first-page":"609","author":"Sanders","year":"2018"},{"issue":"1","key":"10.1016\/j.amjcard.2021.09.047_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCOUTCOMES.111.962688","article-title":"Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993\u20132007","volume":"5","author":"Piccini","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.amjcard.2021.09.047_bib0006","first-page":"339","article-title":"Stroke prevention with oral anticoagulation in older people with atrial fibrillation - A pragmatic approach","volume":"3","author":"Ali","year":"2012","journal-title":"Aging Dis"},{"issue":"6","key":"10.1016\/j.amjcard.2021.09.047_bib0007","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/jcm9061633","article-title":"Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the Aristophanes study","volume":"9","author":"Deitelzweig","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2021.09.047_bib0008","unstructured":"Centers for Disease Control and Prevention. Overweight & Obesity: Adult Obesity Facts. Available at: https:\/\/www.cdc.gov\/obesity\/data\/adult.html. Date: February 11, 2021. Accessed March 5, 2021."},{"issue":"25","key":"10.1016\/j.amjcard.2021.09.047_bib0009","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjcard.2021.09.047_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjcard.2021.09.047_bib0011","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjcard.2021.09.047_bib0012","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.amjcard.2021.09.047_bib0013","first-page":"354","article-title":"ENGAGE AF: effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation","volume":"2013","author":"Kaba","year":"2013","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.amjcard.2021.09.047_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjcard.2021.09.047_bib0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"10.1016\/j.amjcard.2021.09.047_bib0016","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am J Cardiol"},{"issue":"38","key":"10.1016\/j.amjcard.2021.09.047_bib0017","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","article-title":"The 'obesity paradox' in atrial fibrillation: observations from the Aristotle (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial","volume":"37","author":"Sandhu","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.amjcard.2021.09.047_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/rth2.12178","article-title":"Direct oral anticoagulants in extremely obese patients: OK to use?","volume":"3","author":"Moll","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"10.1016\/j.amjcard.2021.09.047_bib0019","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17474086.2018.1517040","article-title":"Anticoagulation at the extremes of body weight: choices and dosing","volume":"11","author":"McCaughan","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.amjcard.2021.09.047_bib0020","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"28","key":"10.1016\/j.amjcard.2021.09.047_bib0021","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.amjcard.2021.09.047_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2167696815621645","article-title":"A primer on inverse probability of treatment weighting and marginal structural models","volume":"4","author":"Thoemmes","year":"2016","journal-title":"Emerg Adulthood"},{"issue":"2","key":"10.1016\/j.amjcard.2021.09.047_bib0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.amjcard.2021.09.047_bib0024","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.amjcard.2021.09.047_bib0025","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \"real-world\" clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjcard.2021.09.047_bib0026","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11239-019-01838-5","article-title":"Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population","volume":"48","author":"Amin","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"10.1016\/j.amjcard.2021.09.047_bib0027","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.amjcard.2021.09.047_bib0028","first-page":"991","article-title":"Exploring the obesity paradox in atrial fibrillation. AFBAR (Atrial Fibrillation Barbanza Area) registry results","volume":"6","author":"Gonz\u00e1lez-Cambeiro","year":"2014","journal-title":"J Atr Fibrillation"},{"issue":"7","key":"10.1016\/j.amjcard.2021.09.047_bib0029","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjmed.2009.11.026","article-title":"Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox","volume":"123","author":"Badheka","year":"2010","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.amjcard.2021.09.047_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amjcard.2010.03.036","article-title":"Obesity and outcomes among patients with established atrial fibrillation","volume":"106","author":"Ardestani","year":"2010","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.amjcard.2021.09.047_bib0031","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijcard.2014.07.264","article-title":"Obesity paradox in patients with atrial fibrillation and heart failure","volume":"176","author":"Wang","year":"2014","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.amjcard.2021.09.047_bib0032","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrcardio.2016.45","article-title":"Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis","volume":"13","author":"Ko","year":"2016","journal-title":"Nat Rev Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921010006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921010006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:40:38Z","timestamp":1757572838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914921010006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"alternative-id":["S0002914921010006"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.09.047","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.09.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}